{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:18:50Z","timestamp":1791685130193,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"SIRIC ILIAD","award":["SIRIC ILIAD"],"award-info":[{"award-number":["SIRIC ILIAD"]}]},{"name":"Institut de cancerologie de l'ouest","award":["Institut de cancerologie de l'ouest"],"award-info":[{"award-number":["Institut de cancerologie de l'ouest"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07619-y","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T23:51:53Z","timestamp":1761954713000},"page":"2403-2413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prospective pilot study with [89Zr]Zr-girentuximab PET\/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE)"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0455-0523","authenticated-orcid":false,"given":"Caroline","family":"Rousseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. F.","family":"Heyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JS","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Taupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vilcot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Campion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"7619_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000. https:\/\/doi.org\/10.1038\/35021093.","journal-title":"Nature"},{"key":"7619_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of Triple-Negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1177.","journal-title":"Cancer Discov"},{"key":"7619_CR3","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045.","journal-title":"Clin Cancer Res"},{"key":"7619_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66.","journal-title":"Nat Rev Clin Oncol"},{"key":"7619_CR5","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1186\/s13058-020-01296-5","volume":"11","author":"S Li","year":"2022","unstructured":"Li S, Bao C, Huang L, Wei JF. Current therapeutic strategies for metastatic Triple-Negative breast cancer: from pharmacists\u2019 perspective. J Clin Med. 2022;11:6021. https:\/\/doi.org\/10.1186\/s13058-020-01296-5.","journal-title":"J Clin Med"},{"key":"7619_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5.","journal-title":"Breast Cancer Res"},{"key":"7619_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature13119","volume":"508","author":"X Chen","year":"2014","unstructured":"Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1\u03b1 pathway. Nature. 2014;508:103\u20137. https:\/\/doi.org\/10.1038\/nature13119.","journal-title":"Nature"},{"key":"7619_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11307-015-0885-x","volume":"18","author":"NK Tafreshi","year":"2016","unstructured":"Tafreshi NK, Lloyd MC, Proemsey JB, Bui MM, Kim J, Gillies RJ, et al. Evaluation of CA-IX and CAXII expression in breast cancer at varied O2 levels: CA-IX is the superior surrogate imaging biomarker of tumor hypoxia. Mol Imaging Biol. 2016;18:219\u201331. https:\/\/doi.org\/10.1007\/s11307-015-0885-x.","journal-title":"Mol Imaging Biol"},{"key":"7619_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-023-01325-9","volume":"18","author":"SAK Shamis","year":"2023","unstructured":"Shamis SAK, Edwards J, McMillan DC. The relationship between carbonic anhydrase IX (CA-IX) and patient survival in breast cancer: systematic review and meta\u2013analysis. Diagn Pathol. 2023;18:46. https:\/\/doi.org\/10.1186\/s13000-023-01325-9.","journal-title":"Diagn Pathol"},{"key":"7619_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/sj.bjc.6604844","volume":"100","author":"EY Tan","year":"2009","unstructured":"Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, et al. The key hypoxia regulated gene CA-IX is upregulated in basal-like breast tumors and is associated with resistance to chemotherapy. Br J Cancer. 2009;100:405\u201311. https:\/\/doi.org\/10.1038\/sj.bjc.6604844.","journal-title":"Br J Cancer"},{"key":"7619_CR11","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1158\/0008-5472","volume":"71","author":"Y Lou","year":"2011","unstructured":"Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Can Res. 2011;71:3364\u201376. https:\/\/doi.org\/10.1158\/0008-5472.","journal-title":"Can Res"},{"key":"7619_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s12253-010-9355-6","volume":"17","author":"L Beketic-Oreskovic","year":"2011","unstructured":"Beketic-Oreskovic L, Ozretic P, Rabbani ZN, Jackson IL, Sarcevic B, Levanat S, et al. Prognostic significance of carbonic anhydrase IX (CA-IX), endoglin (CD105) and 8-hydroxy-2\u2032-deoxyguanosine (8-OHdG) in breast cancer patients. Pathol Oncol Res. 2011;17:593\u2013603. https:\/\/doi.org\/10.1007\/s12253-010-9355-6.","journal-title":"Pathol Oncol Res"},{"key":"7619_CR13","doi-asserted-by":"publisher","unstructured":"Numprasit W, Yangngam S, Prasopsiri J, Quinn JA, Edwards J, Thuwajit C. (2023) Carbonic anhydrase IX-related tumoral hypoxia predicts worse prognosis in breast cancer: A systematic review and meta-analysis. Front Med.2023;10:1087270. https:\/\/doi.org\/10.3389\/fmed.2023.1087270","DOI":"10.3389\/fmed.2023.1087270"},{"key":"7619_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/oncotarget.422","volume":"3","author":"PC McDonald","year":"2012","unstructured":"McDonald PC, Winum J-Y, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 2012;3:84\u201397. https:\/\/doi.org\/10.18632\/oncotarget.422.","journal-title":"Oncotarget"},{"key":"7619_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030838","volume":"19","author":"K Tatiparti","year":"2018","unstructured":"Tatiparti K, Sau S, Gawde KA, Iyer AK. Copper-Free \u2018Click\u2019 Chemistry-Based synthesis and characterization of carbonic Anhydrase-IX anchored Albumin-Paclitaxel nanoparticles for targeting tumor hypoxia. Int J Mol Sci. 2018;19:838. https:\/\/doi.org\/10.3390\/ijms19030838.","journal-title":"Int J Mol Sci"},{"key":"7619_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/ijc.2910380406","volume":"38","author":"E Oosterwijk","year":"1986","unstructured":"Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, et al. Monoclonal antibody G 250 recognizes a determinant present in renal\u2013cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489\u201394. https:\/\/doi.org\/10.1002\/ijc.2910380406.","journal-title":"Int J Cancer"},{"key":"7619_CR17","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","volume":"25","author":"B Shuch","year":"2024","unstructured":"Shuch B, Pantuck AJ, Bernhard JC, Morris MA, Master V, Scott AM, et al. [89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25:1277\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(24)00402-9.","journal-title":"Lancet Oncol"},{"key":"7619_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21197146","volume":"21","author":"J Courcier","year":"2020","unstructured":"Courcier J, de la Taille A, Nourieh M, Leguerney I, Lassau N, Ingels A. Carbonic anhydrase IX in renal cell carcinoma, implications for disease management. Int J Mol Sci. 2020;21:7146. https:\/\/doi.org\/10.3390\/ijms21197146.","journal-title":"Int J Mol Sci"},{"key":"7619_CR19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/cancers11071002","volume":"11","author":"EE Hedlund","year":"2019","unstructured":"Hedlund EE, McDonald PC, Nemirovsky O, Awrey S, Jensen LDE, Dedhar S. Harnessing induced essentiality: targeting carbonic anhydrase IX and angiogenesis reduces lung metastasis of triple negative breast cancer xenografts. Cancers. 2019;11:1002. https:\/\/doi.org\/10.3390\/cancers11071002.","journal-title":"Cancers"},{"key":"7619_CR20","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00259-019-04358-9","volume":"46","author":"SR Verhoeff","year":"2019","unstructured":"Verhoeff SR, van Es SC, Boon E, van Helden E, Angus L, Elias SG, et al. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG PET\/CT in patients with newly diagnosed metastatic renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019;46:1931\u20139. https:\/\/doi.org\/10.1007\/s00259-019-04358-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7619_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.eururo.2015.11.033","volume":"69","author":"CH Muselaers","year":"2016","unstructured":"Muselaers CH, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, et al. Phase 2 study of lutetium 177\u2013Labeled Anti\u2013Carbonic anhydrase IX monoclonal antibody Girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2016;69:767\u201370. https:\/\/doi.org\/10.1016\/j.eururo.2015.11.033.","journal-title":"Eur Urol"},{"key":"7619_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071190","volume":"17","author":"C Rousseau","year":"2025","unstructured":"Rousseau C, Baumgartner P, Heymann MF, Taupin M, Geffroy M, Chatal JF, et al. Preclinical and clinical feasibility studies as the first step before forthcoming intravesical instillation of [211At]At-anti-CA-IX antibody (ATO-101\u2122) study in patients with non-muscle-invasive bladder cancer unresponsive to standard of care. Cancers (Basel). 2025;17:1190. https:\/\/doi.org\/10.3390\/cancers17071190.","journal-title":"Cancers (Basel)"},{"key":"7619_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040508","volume":"17","author":"H Suzuki","year":"2024","unstructured":"Suzuki H, Kannaka K, Uehara T. Approaches to reducing normal tissue radiation from radiolabeled antibodies. Pharmaceuticals. 2024;17:508. https:\/\/doi.org\/10.3390\/ph17040508.","journal-title":"Pharmaceuticals"},{"key":"7619_CR24","first-page":"112","volume":"38","author":"WE Meijs","year":"1997","unstructured":"Meijs WE, Haisma HJ, Klok RP, van Gog FB, Kievit E, Pinedo HM, et al. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice. J Nucl Med. 1997;38:112\u20138. PMID: 8998164.","journal-title":"J Nucl Med"},{"key":"7619_CR25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/jlcr.3628","volume":"61","author":"D Vivier","year":"2018","unstructured":"Vivier D, Sharma SK, Zeglis BM. Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging. J Labelled Comp Radiopharm. 2018;61:672\u201392. https:\/\/doi.org\/10.1002\/jlcr.3628.","journal-title":"J Labelled Comp Radiopharm"},{"key":"7619_CR26","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/sj.bjc.6601727","volume":"90","author":"F Stessels","year":"2004","unstructured":"Stessels F, Van den Eynden G, Van der Auwera I, Salgado R, Van den Heuvel E, Harris AL, et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer. 2004;90:1429\u201336. https:\/\/doi.org\/10.1038\/sj.bjc.6601727.","journal-title":"Br J Cancer"},{"key":"7619_CR27","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1046\/j.13652559.2003.01629.x","volume":"42","author":"CG Colpaert","year":"2003","unstructured":"Colpaert CG, Vermeulen PB, Van Beest P, Soubry A, Goovaerts G, Dirix LY, et al. Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition. Histopathology. 2003;42:530\u201340. https:\/\/doi.org\/10.1046\/j.13652559.2003.01629.x.","journal-title":"Histopathology"},{"key":"7619_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119181","volume":"10","author":"WJ Huang","year":"2015","unstructured":"Huang WJ, Jeng YM, Lai HS, Fong IU, Sheu FY, Lai PL, et al. Expression of hypoxic marker carbonic anhydrase IX predicts poor prognosis in resectable hepatocellular carcinoma. PLoS ONE. 2015;10:e0119181. https:\/\/doi.org\/10.1371\/journal.pone.0119181.","journal-title":"PLoS ONE"},{"key":"7619_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2967\/jnumed.114.144840","volume":"56","author":"SF Oosting","year":"2015","unstructured":"Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, et al. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med. 2015;56:63\u20139. https:\/\/doi.org\/10.2967\/jnumed.114.144840.","journal-title":"J Nucl Med"},{"key":"7619_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf4408","volume":"7","author":"J Berthelet","year":"2021","unstructured":"Berthelet J, Wimmer VC, Whitfield HJ, Serrano A, Boudier T, Mangiola S, et al. The site of breast cancer metastases dictates their clonal composition and reversible transcriptomic profile. Sci Adv. 2021;7:eabf4408. https:\/\/doi.org\/10.1126\/sciadv.abf4408.","journal-title":"Sci Adv"},{"key":"7619_CR31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.neo.2020.09.009","volume":"22","author":"S Taurin","year":"2020","unstructured":"Taurin S, Alkhalifa H. Breast cancers, mammary stem cells, and cancer stem cells, characteristics, and hypotheses. Neoplasia. 2020;22:663\u201378. https:\/\/doi.org\/10.1016\/j.neo.2020.09.009.","journal-title":"Neoplasia"},{"key":"7619_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189120","volume":"1879","author":"R Ronca","year":"2024","unstructured":"Ronca R, Supuran CT. Carbonic anhydrase IX: an atypical target for innovative therapies in cancer. Biochimica et Biophysica Acta (BBA). 2024;1879:189120. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189120.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"7619_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4274\/ejbh.galenos.2024.2024-6-1","volume":"21","author":"\u00d6A Solmaz","year":"2025","unstructured":"Solmaz \u00d6A, Kutluer N, Bozan MB. Carbonic anhydrase IX enzyme in triple negative breast carcinoma: relationship with prognostic factors and response to neoadjuvant chemotherapy. Eur J Breast Health. 2025;21:57\u201362. https:\/\/doi.org\/10.4274\/ejbh.galenos.2024.2024-6-1.","journal-title":"Eur J Breast Health"},{"key":"7619_CR34","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2967\/jnumed.119.236000","volume":"61","author":"C Rousseau","year":"2020","unstructured":"Rousseau C, Goldenberg DM, Colombi\u00e9 M, S\u00e9bille JC, Meingan P, Ferrer L, et al. Initial clinical results of a novel Immuno-PET theranostic probe in human epidermal growth factor receptor 2-negative breast cancer. J Nucl Med. 2020;61:1205\u201311. https:\/\/doi.org\/10.2967\/jnumed.119.236000.","journal-title":"J Nucl Med"},{"key":"7619_CR35","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2967\/jnumed.120.252791","volume":"62","author":"C Bodet-Milin","year":"2021","unstructured":"Bodet-Milin C, Faivre-Chauvet A, Carlier T, Ansquer C, Rauscher A, Frampas E, et al. Anti-CEA pretargeted immuno-PET shows higher sensitivity than DOPA PET\/CT in detecting relapsing metastatic medullary thyroid carcinoma: post hoc analysis of the iPET-MTC study. J Nucl Med. 2021;62:1221\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.252791.","journal-title":"J Nucl Med"},{"key":"7619_CR36","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00259-021-05271-w","volume":"48","author":"RIJ Merkx","year":"2021","unstructured":"Merkx RIJ, Lobeek D, Konijnenberg M, Jim\u00e9nez-Franco LD, Kluge A, Oosterwijk E, et al. Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:3277\u201385. https:\/\/doi.org\/10.1007\/s00259-021-05271-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7619_CR37","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.123.266392","volume":"65","author":"R Yeh","year":"2024","unstructured":"Yeh R, O\u2019Donoghue JA, Jayaprakasam VS, Mauguen A, Min R, Park S, et al. First-in-human evaluation of site-specifically labeled 89Zr-Pertuzumab in patients with HER2-positive breast cancer. J Nucl Med. 2024;65:386\u201393. https:\/\/doi.org\/10.2967\/jnumed.123.266392.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07619-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07619-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07619-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:39:01Z","timestamp":1771479541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07619-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7619"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07619-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical study was funded by SIRIC ILIAD and Institut de Canc\u00e9rologie de l\u2019Ouest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}},{"value":", preliminary results were selected for Oral communication at EANM 2022 in Barcelone and Poster session at San Antonio Breast Cancer Symposium 2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"For OPALESCENCE study"}},{"value":"Ethical approval was obtained from the Sud-Est VI Clermont-Ferrand Review Board (21.01.13.57453-AU_1682). All patients signed a written informed consent prior to participation in this study (2020-003805-71). (NCT04758780)","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent to publish"}}]}}